Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / August 6, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2020. "Following positive topline results from the primary analysis of the ROCKstar pivotal trial of belum...
Ultra-thinly traded micro cap Liminal BioSciences ( LMNL +129.1% ) is up on a whopping 105x surge in volume, albeit on a relatively modest 1.2M shares, in reaction to its announcement that subsidiary Prometic Plasma Resources has started collecting convalescent plasma from people who hav...
NEW YORK, NY / ACCESSWIRE / June 23, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors. KD033 is a nove...
NEW YORK, NY / ACCESSWIRE / June 11, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Raymond James 2020 Virtual Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ET. A l...
Kadmon Holdings (NYSE: KDMN ) raised $50M in its at-the-market facility via the sale of ~11.1M common shares at then-prevailing market prices. More news on: Kadmon Holdings, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
NEW YORK, NY / ACCESSWIRE / June 5, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that it has raised gross proceeds of $50.0 million through its At-The-Market (ATM) facility, including participation based on interest received from existing shareholders and new healthcare specialis...
NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2020 Virtual Global Healthcare Conference on Thursday, June 4, 2020 at 4:00 p.m. ET. A live audio we...
This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...
Kadmon Holdings Reports Positive Topline Results Kadmon Holdings Inc. ( KDMN ) announced positive topline data from the pivotal trial of belumosudil (KD025). The trial was designed to evaluate the drug candidate in patients suffering from chronic graft-versus-host disease (cGVHD) who hav...
Shares of Kadmon Holdings (NYSE: KDMN) are getting a boost on Thursday after the biopharmaceutical company reported positive results from a clinical trial for one of its most promising pipeline candidates, KD025. Kadmon Holdings' stock is up by 8.4% as of 1:05 p.m. today. KD025 is being inv...
News, Short Squeeze, Breakout and More Instantly...
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadm...
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kadmon Holdings, Inc. Skyrockets Amid Entering Definitive Merger Agreement with Sanofi Kadmon Holdings, Inc. (NASDAQ: KDMN) surged 73% in premarket trading after entering...